All News

Data from the trial that led to the FDA approval demonstrated that Keytruda reduced the risk of progression or death in patients with relapsed or refractory classical Hodgkin lymphoma by 35%, compared to Adcetris.

The average overall survival for patients who reported consuming four or more cups of coffee per day prior to trial enrollment was 39 months.

Prostate cancer treatment can be detrimental to bone and muscle health, but an exercise regimen and healthy eating habits can help.

In an interview with CURE®, Dr. Trisha Wise-Draper discusses new findings that show an increased mortality risk for patients with cancer receiving systemic treatments who subsequently contracted COVID-19.

Researchers found that neoadjuvant chemotherapy with intense dose-dense Ellence (epirubicin), Taxol (paclitaxel), and Cytoxan (cyclophosphamide) (iddEPC) demonstrated significant disease-free survival benefits in the treatment of patients with HR+/HER2- breast cancer.

Everyone has a role to play in decreasing Clostridioides difficile infection rates on oncology units, recent research shows.

For Metastatic Breast Cancer Awareness Day on Oct. 13, 2020, here’s a round-up of fast facts and the latest news and updates in this disease space.

Combining the immunotherapy Keytruda with a CAR-T cell therapy that targets the proteins CD19 and CD22 generates complete responses with minimal side effects, results from an early study demonstrate.

Some patients are better suited for surgery than others. In general, patients with widespread metastatic disease are also not good candidates for surgery, particularly if their cancer has spread beyond the prostate to areas like the liver, lungs, and bones.

Active surveillance can be used for many patients with prostate cancer; however, when localized, radiation therapy is an option.

In this essay, a patient with cancer shares how her oncology nurse was a true comfort through the cancer journey and a true friend.

One patient talks about how their oncology nurse was a hero to not just her, but many other patients in the clinic.

Oncology nurses are there for nearly every step of a patient's cancer journey, but along the way, they can help illuminate life's beauty.

An oncology nurse clinical leader details how one of her staff members brought out the best in those around her, patients and nurses alike.

From a child from Indiana donating funds from a pumpkin sale to a local cancer charity, to a researcher at Stony Brook University being sentenced to prison after stealing $225,000 in cancer research funds, here’s what’s happening in the cancer landscape this week.

Adding the targeted drug Tukysa (tucatinib) to Herceptin (trastuzumab) and the chemotherapy Xeloda (capecitabine) lengthens life and time until disease progression in patients, without decreasing their health-related quality of life, researchers found in a follow-up to the HER2CLIMB study.

Recent study results demonstrated that there was contamination of popular chemotherapy agents in both patient and staff bathrooms of a cancer center.

“Collectively, our mature data provide the most definitive evidence supporting current guidelines, that HDT/ASCT should not be offered to unselected patient(s) (with follicular lymphoma) in the frontline setting,” the authors wrote.

Legendary Van Halen lead guitarist, Eddie Van Halen, died on Tuesday from cancer. He was 65.

In a clinical trial, adding the CDK4/6 inhibitor Ibrance (palbociclib) to the hormonal treatment Faslodex (fulvestrant) delayed disease progression in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.

Overall survival was better with hepatic arterial infusion chemotherapy compared with transarterial chemoembolization, according to phase 3 study findings.

On social media, CURE® recently asked its readers to share the most important lesson cancer taught them.

“The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” Dr. Sumanta Kumar Pal, co-director of the Kidney Cancer Program at City of Hope in California, said during a presentation of the clear cell renal cell carcinoma cohort.